Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Retained Earnings (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Retained Earnings for 11 consecutive years, with -$459.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 2.72% to -$459.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$459.2 million through Dec 2025, down 2.72% year-over-year, with the annual reading at -$459.2 million for FY2025, 2.72% down from the prior year.
  • Retained Earnings for Q4 2025 was -$459.2 million at Marker Therapeutics, roughly flat from -$457.5 million in the prior quarter.
  • The five-year high for Retained Earnings was -$365.0 million in Q1 2021, with the low at -$459.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$426.6 million, with a median of -$433.2 million recorded in 2023.
  • The sharpest move saw Retained Earnings dropped 11.78% in 2022, then decreased 1.31% in 2024.
  • Over 5 years, Retained Earnings stood at -$398.1 million in 2021, then fell by 7.52% to -$428.0 million in 2022, then dropped by 1.92% to -$436.3 million in 2023, then dropped by 2.46% to -$447.0 million in 2024, then fell by 2.72% to -$459.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$459.2 million, -$457.5 million, and -$455.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.